Literature DB >> 19189866

Apoptosis in pemphigus.

Enno Schmidt1, Jens Waschke.   

Abstract

Pemphigus is a severe autoimmune blistering skin disease. The two main forms of pemphigus, pemphigus vulgaris and pemphigus foliaceus, are primarily caused by autoantibodies against the desmosomal cadherins desmoglein 1 and desmoglein 3. The histopathological hallmark is the loss of cell adhesion between neighbouring keratinocytes, a phenomenon called acantholysis. Various underlying mechanisms of acantholysis have been described including apoptosis. The role of apoptosis in pemphigus pathogenesis is unclear at present and the focus of this review. While characteristic signs of apoptosis can be found in lesional patient skin these can be missing in very early lesions of macroscopically perilesional skin where acantholysis is detected by light microscopy. Under experimental conditions, activation of apoptotic signalling can be induced by pemphigus IgG as well as by pemphigus serum which contains large amounts of Fas ligand. Studies using caspase inhibitors which were effective to block acantholysis indicate that the apoptotic machinery contributes to cell dissociation. However, acantholysis can occur in the absence of apoptosis which demonstrates that apoptosis is not strictly required for skin blistering in pemphigus. Taken together, signalling events leading to apoptosis including activation of executioner caspases are not required but may participate in the cellular response to pemphigus autoantibodies leading to acantholysis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189866     DOI: 10.1016/j.autrev.2009.01.011

Source DB:  PubMed          Journal:  Autoimmun Rev        ISSN: 1568-9972            Impact factor:   9.754


  21 in total

Review 1.  Cadherins: cellular adhesive molecules serving as signalling mediators.

Authors:  Mark Yulis; Dennis H M Kusters; Asma Nusrat
Journal:  J Physiol       Date:  2018-08-08       Impact factor: 5.182

2.  No evidence of apoptotic cells in pemphigus acantholysis.

Authors:  Ineke C Janse; Gerda van der Wier; Marcel F Jonkman; Hendri H Pas; Gilles F H Diercks
Journal:  J Invest Dermatol       Date:  2014-01-31       Impact factor: 8.551

3.  Experimental human cell and tissue models of pemphigus.

Authors:  Gerda van der Wier; Hendri H Pas; Marcel F Jonkman
Journal:  Dermatol Res Pract       Date:  2010-05-26

4.  A hypothesis concerning a potential involvement of ceramide in apoptosis and acantholysis induced by pemphigus autoantibodies.

Authors:  Wendy B Bollag
Journal:  Dermatol Res Pract       Date:  2010-05-18

Review 5.  Desmosomal Cadherins in Health and Disease.

Authors:  Marihan Hegazy; Abbey L Perl; Sophia A Svoboda; Kathleen J Green
Journal:  Annu Rev Pathol       Date:  2021-08-23       Impact factor: 23.472

6.  Superficial dsg2 expression limits epidermal blister formation mediated by pemphigus foliaceus antibodies and exfoliative toxins.

Authors:  Donna Brennan; Ying Hu; Walid Medhat; Alicia Dowling; My G Mahoney
Journal:  Dermatol Res Pract       Date:  2010-06-09

Review 7.  Pemphigus autoimmunity: hypotheses and realities.

Authors:  Sergei A Grando
Journal:  Autoimmunity       Date:  2011-09-23       Impact factor: 2.815

8.  Preclinical studies identify non-apoptotic low-level caspase-3 as therapeutic target in pemphigus vulgaris.

Authors:  Camille Luyet; Katja Schulze; Beyza S Sayar; Denise Howald; Eliane J Müller; Arnaud Galichet
Journal:  PLoS One       Date:  2015-03-06       Impact factor: 3.240

Review 9.  Pemphigus-A Disease of Desmosome Dysfunction Caused by Multiple Mechanisms.

Authors:  Volker Spindler; Jens Waschke
Journal:  Front Immunol       Date:  2018-02-01       Impact factor: 7.561

10.  Nanorobotic investigation identifies novel visual, structural and functional correlates of autoimmune pathology in a blistering skin disease model.

Authors:  Kristina Seiffert-Sinha; Ruiguo Yang; Carmen K Fung; King W Lai; Kevin C Patterson; Aimee S Payne; Ning Xi; Animesh A Sinha
Journal:  PLoS One       Date:  2014-09-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.